Coalition for Epidemic Preparedness Innovations & Serum Institute of India

Coalition for Epidemic Preparedness Innovations: The Coalition for Epidemic Preparedness Innovations (CEPI) is a key funder, committing approximately $60 million to accelerate the development of Ebola Bundibugyo vaccines, and is crucial in coordinating the global response.

Serum Institute of India: The Serum Institute of India is manufacturing a vaccine candidate developed by the University of Oxford, receiving up to $8.6 million from CEPI for its development.

Coalition for Epidemic Preparedness Innovations: Funding vaccine development efforts, including the Oxford and Hilleman candidates. Its investment is critical for accelerating vaccine research.

Serum Institute of India: Manufactured a stockpile of 620,000 doses of the Oxford vaccine candidate. Its manufacturing capacity is crucial for potential large-scale deployment.

Coalition for Epidemic Preparedness Innovations: The Coalition for Epidemic Preparedness Innovations (CEPI) funds vaccine development and is assessing potential Ebola vaccine candidates, aiming for a rapid response.

Serum Institute of India: The Serum Institute of India is manufacturing doses of a vaccine candidate built on the University of Oxford/AstraZeneca platform, which could be used for clinical trials against the Bundibugyo ebolavirus.